Heart failure & cardiomyopathies
Rationale and design of the TeleClinical Care Cardiac (TCC-Cardiac) trial: A pragmatic randomized trial of adjunctive virtual models of care in the secondary prevention of cardiovascular events
Study context
- Population
- Patients being discharged home following an admission with acute myocardial infarction (MI) or decompensated heart failure (HF)participants enrolled by the final enrolment date (October 2023) · Cohort 1 553 · Cohort 2 161 · Cohort 3 159
- Participants
- 873 patients
- Planned comparison
- TCCCardiac model of care vs usual care alone in Cohort 1; TCC-Text vs usual care alone in Cohort 2
- Cohort 3n = 159
- Primary endpoint
- Readmission rates in Cohort 1
- Follow-up
- six-month
Methodological details3 cohorts divided pragmatically by access to technology, rationale and design
- 3 cohorts divided pragmatically by access to technology
- Rationale and design
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Trial conduct and enrolment
- Trial conduct and enrolment — Trial began
- July 2021
- Trial conduct and enrolment — Recruitment slower than expected due to delays and interruptions related to COVID-19; final enrolment date
- October 2023
- Trial conduct and enrolment — Data linkage anticipated
- May 2025
- Trial conduct and enrolment: includes a 6-month delay to ensure 12-month data will be available for all study patients, followed by the analysis of results
Original publication
Rationale and design of the TeleClinical Care Cardiac (TCC-Cardiac) trial: A pragmatic randomized trial of adjunctive virtual models of care in the secondary prevention of cardiovascular events. Am Heart J. Published 11 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →